Johnson & Johnson Gets FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia
By Elias Schisgall
Johnson & Johnson received approval from the Food and Drug Administration for Imaavy to treat a rare autoantibody disease in adults and children at least 12 years old who previously took or are currently taking corticosteroids.
The company said the drug, also known as nipocalimab-aahu, is now the first therapy to be proven safe and effective to specifically treat the disease, called warm autoimmune hemolytic anemia.
The drug had undergone FDA priority review, Johnson & Johnson said.
"Today's announcement marks the second approval for Imaavy and is an extraordinary milestone for people living with warm autoimmune hemolytic anemia, an underserved community that has waited far too long for an FDA-approved treatment," Johnson & Johnson's global immunology therapeutic area head, David Lee, said on Monday.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
August 24, 2026 20:06 ET (00:06 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States